Catabasis Pharmaceuticals (NASDAQ:CATB) issued its earnings results on Tuesday. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02), Fidelity Earnings reports.

CATB traded up $0.43 on Wednesday, reaching $8.34. The stock had a trading volume of 78,205 shares, compared to its average volume of 99,049. Catabasis Pharmaceuticals has a fifty-two week low of $3.60 and a fifty-two week high of $17.60. The stock has a market cap of $91.73 million, a PE ratio of -1.63 and a beta of 1.72.

A number of brokerages have issued reports on CATB. ValuEngine raised Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. Wedbush reaffirmed a “buy” rating and issued a $20.00 target price on shares of Catabasis Pharmaceuticals in a report on Monday, March 18th. Finally, Zacks Investment Research raised Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a report on Monday, February 4th. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $29.38.

A number of institutional investors and hedge funds have recently modified their holdings of CATB. Oxford Asset Management LLP purchased a new position in shares of Catabasis Pharmaceuticals in the first quarter valued at $590,000. Renaissance Technologies LLC grew its position in shares of Catabasis Pharmaceuticals by 247.6% in the first quarter. Renaissance Technologies LLC now owns 124,164 shares of the biotechnology company’s stock valued at $983,000 after purchasing an additional 88,445 shares in the last quarter. Northern Trust Corp grew its position in shares of Catabasis Pharmaceuticals by 71.6% in the first quarter. Northern Trust Corp now owns 28,735 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 11,987 shares in the last quarter. Federated Investors Inc. PA grew its position in shares of Catabasis Pharmaceuticals by 109.8% in the first quarter. Federated Investors Inc. PA now owns 2,189,400 shares of the biotechnology company’s stock valued at $17,340,000 after purchasing an additional 1,146,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Catabasis Pharmaceuticals in the first quarter valued at $1,174,000. 21.59% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2019/05/15/catabasis-pharmaceuticals-catb-releases-quarterly-earnings-results-misses-expectations-by-0-02-eps.html.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD).

Featured Story: What is the return on assets (ROA) ratio?

Earnings History for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.